-
Your selected country is
Brazil
- Change country/language
Old Browser
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
BD Simultest™ Anti-Human Kappa FITC/Lambda PE
(RUO (GMP))Anti-Human Kappa FITC/Lambda PE
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Description
Anti-Kappa: TB28-2 is derived from hybridization of mouse P3-X63-Ag8.653 myeloma cells with cells from CB6 (BC57b X BALB/c) mice immunized with human IgG, κ myeloma protein. Anti-Lambda: 1-155-2 is derived from hybridization of mouse P3-X63-Ag8.653 myeloma cells with cells from BALB C/J mice immunized with human IgA1, λ myeloma protein. Anti-Kappa is specific for kappa light chains of human immunoglobulins. Anti-Lambda is specific for lambda light chains of human immunoglobulins.
Preparation And Storage
The Simultest reagent is supplied as a combination of Anti-Kappa FITC and Anti-Lambda PE in 1.0 mL of phosphate-buffered saline. Buffered saline contains gelatin and 0.1% sodium azide. The vial should be stored at 2° to 8°C and protected from prolonged exposure to light. Simultest reagents should not be frozen. Each Simultest reagent is stable for the period shown on the bottle label when stored as directed.
Description | Clone | Isotype | EntrezGene ID |
---|---|---|---|
N/A | TB28-2 | IgG1, κ | N/A |
FITC Mouse Anti-Human Ig, λ Light Chain | 1-155-2 | IgG1, λ | 3535 |
Development References (9)
-
Ault KA. Flow cytometric evaluation of normal and neoplastic B cells. In: Rose NR, Friedman H, Fahey JL. Rose NR, Friedman H, Fahey JL, ed. Manual of Clinical Laboratory Immunology. 3rd ed.. Washington, DC: American Society for Microbiology; 1986:247-253. View Reference
-
Foon KA, Todd RF. Immunologic classification of leukemia and lymphoma.. Blood. 1986; 68(1):1-31. (Biology). View Reference
-
Harris NL, Data RE. The distribution of neoplastic and normal B-lymphoid cells in nodular lymphomas: use of an immunoperoxidase technique on frozen sections.. Hum Pathol. 1982; 13(7):610-7. (Biology). View Reference
-
Meis JM, Osborne BM, Butler JJ. A comparative marker study of large cell lymphoma, Hodgkin's disease, and true histiocytic lymphoma in paraffin-embedded tissue.. Am J Clin Pathol. 1986; 86(5):591-9. (Biology). View Reference
-
Picker LJ, Weiss LM, Medeiros LJ, Wood GS, Warnke RA. Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma.. Am J Pathol. 1987; 128(1):181-201. (Biology). View Reference
-
Smith BR, Weinberg DS, Robert NJ, et al. Circulating monoclonal B lymphocytes in non-Hodgkin's lymphoma.. N Engl J Med. 1984; 311(23):1476-81. (Biology). View Reference
-
Tubbs RR, Sheibani K, Weiss RA, Sebek BA, Deodhar SD. Tissue immunomicroscopic evaluation of monoclonality of B-cell lymphomas: comparison with cell suspension studies.. Am J Clin Pathol. 1981; 76(1):24-8. (Biology). View Reference
-
Têtu B, Manning JT, Ordóñez NG. Comparison of monoclonal and polyclonal antibodies directed against immunoglobulin light and heavy chains in non-Hodgkin's lymphoma.. Am J Clin Pathol. 1986; 85(1):25-31. (Biology). View Reference
-
Weinberg DS, Pinkus GS, Ault KA. Cytofluorometric detection of B cell clonal excess: a new approach to the diagnosis of B cell lymphoma.. Blood. 1984; 63(5):1080-7. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Although not required, these products are manufactured in accordance with Good Manufacturing Practices.